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PCSK9 R46L, Low-Density Lipoprotein
Cholesterol Levels, and Risk of Ischemic Heart Disease
3 Independent Studies and Meta-Analyses
Marianne Benn, MD, PHD,*‡§ Børge G. Nordestgaard, MD, DMSC,‡§ Peer Grande, MD, DMSC,†
Peter Schnohr, MD, DMSC, Anne Tybjærg-Hansen, MD, DMSC*§
Copenhagen, Denmark
Objectives The aim of this study was to examine the effect of PCSK9 R46L on low-density lipoprotein cholesterol (LDL-C),
risk of ischemic heart disease (IHD), and mortality.
Background The 46L allele has been associated with reductions in LDL-C and risk of IHD, but results vary between studies.
Methods We determined the association of R46L genotype with LDL-C, risk of IHD, myocardial infarction (MI), and mortal-
ity in the prospective CCHS (Copenhagen City Heart Study) (n  10,032) and validated the results in: 1) the
cross-sectional CGPS (Copenhagen General Population Study) (n  26,013); and 2) the case-control CIHDS
(Copenhagen Ischemic Heart Disease Study) (n  9,654). We also performed meta-analyses of present and pre-
vious studies (n  66,698).
Results In carriers (2.6%) versus noncarriers, the 46L allele was associated with reductions in LDL-C of 0.35 to 0.55
mmol/l (11% to 16%) from 20 to 80 years in the general population (CCHS and CGPS; p values 0.0001).
Observed risk reductions for IHD in 46L allele carriers were: 6% in the CCHS study (hazard ratio [HR]: 0.94;
95% confidence interval [CI]: 0.68 to 1.31), 46% in the CGPS study (odds ratio [OR]: 0.54; 95% CI: 0.39 to 0.77),
18% in the CIHDS study (OR: 0.82; 95% CI: 0.55 to 1.21), and 30% in the studies combined (OR: 0.70; 95% CI:
0.58 to 0.86). In the CCHS study, HR for mortality was 1.18 (95% CI: 0.93 to 1.50). In meta-analyses, 46L allele
carriers had a 12% (0.43 mmol/l) reduction in LDL-C and a 28% reduction in risk of IHD (HR: 0.72; 95% CI:
0.62 to 0.84), similar to results in the CCHS, CGPS, and CIHDS studies combined. However, the observed
12% (0.43 mmol/l) reduction in LDL-C theoretically predicted an only 5% reduction in risk of IHD (HR: 0.95;
95% CI: 0.92 to 0.97).
Conclusions The PCSK9 46L allele was associated with reductions in LDL-C from 20 to 80 years in the general population.
The reduction in risk of IHD was larger than predicted by the observed reduction in LDL-C alone. This could be
because genotype is a better predictor of lifelong exposure to LDL-C than LDL-C measured in adult life. (J Am
Coll Cardiol 2010;55:2833–42) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.044t
l
a
(
m
a
w
1
c
c
wroprotein convertase subtilisin/kexin type 9 (PCSK9) mod-
lates plasma levels of low-density lipoprotein cholesterol
LDL-C) by promoting the degradation of low-density
ipoprotein receptors (LDLRs), the primary pathway for the
emoval of low-density lipoprotein (LDL) from the circu-
ation. The PCSK9 seems to interfere with recycling of the
DLR by targeting the receptor to the lysosome for degrada-
rom the Departments of *Clinical Biochemistry and †Cardiology, Rigshospitalet,
Department of Clinical Biochemistry and §Copenhagen General Population Study,
erlev Hospital, and the Copenhagen City Heart Study, Bispebjerg Hospital,
niversity of Copenhagen, Copenhagen, Denmark. This work was supported by the
anish Medical Research Council, the Danish Heart Foundation, the Research Fund
t Rigshospitalet, Copenhagen University Hospital, Chief Physician Johan Boserup
nd Lise Boserup’s Fund, Ingeborg and Leo Dannin’s Grant, and Henry Hansen and
ife’s Grant, Copenhagen, Denmark.a
Manuscript received April 7, 2009; revised manuscript received February 2, 2010,
ccepted February 8, 2010.ion, leading to reduced clearance of LDL-C from the circu-
ation (1–3). Gain-of-function mutations in PCSK9 are rare
nd cause hypercholesterolemia and ischemic heart disease
IHD) (4), whereas loss-of-function mutations are more com-
on and are associated with reduced plasma levels of LDL-C
nd protection from IHD (5,6).
See page 2843
The R46L polymorphism in PCSK9 has been associated
ith reductions in LDL-C of 0.28 to 0.54 mmol/l (9% to
5%) (6–10) and with a 47% reduction in risk of IHD in
arriers versus noncarriers (6). This lower risk of IHD is
onsiderably greater than that expected from statin trials,
here a similar reduction in LDL-C would have caused anpproximately 9% to 15% reduction in risk (11). This
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PCSK9 and Ischemic Heart Disease June 22, 2010:2833–42discrepancy between predicted
and observed risk has been sug-
gested to be due to the presumed
life-long reduction in levels of
LDL-C associated with this ge-
netic variant, as opposed to the
short-term evaluation of effect in
statin trials (6). Because of this, it
has been argued that early and
more aggressive LDL reduction
is needed (12,13). A reduction in
risk of IHD could also translate
into a reduced mortality, but this
has never been examined for
PCSK9 R46L.
We tested the hypothesis that
the PCSK9 46L allele is associ-
ated with lower LDL-C levels in
all age groups from 20 to 80
ears, and with reduced risk of IHD, myocardial infarction
MI), and mortality. We genotyped 45,699 individuals from
independent Danish studies: the prospective CCHS
Copenhagen City Heart Study) (n  10,032), the cross-
ectional CGPS (Copenhagen General Population Study)
n  26,013), and a case-control study, the CIHDS
Copenhagen Ischemic Heart Disease Study) (n  9,654).
inally, the association of the PCSK9 R46L genotype with
DL-C levels and risk of IHD were summarized in
eta-analyses including previous and present studies.
ethods
ubjects. Studies were approved by institutional review
oards and Danish ethical committees (Nos. [KF]V.100.
039/91, [KF]01-144/01, KA93125, and KA99039) and
onducted according to the Declaration of Helsinki. In-
ormed consent was obtained from participants. All partic-
pants were white and of Danish descent. No participants
ppeared in more than 1 of the 3 studies, permitting
ndependent confirmation of the findings in each group.
he CCHS trial. CCHS is a prospective study of a general
opulation initiated in 1976 to 1978 with follow-up exam-
nations from 1981 to 1983, 1991 to 1994, and 2001 to
003 (14). Individuals were selected on the basis of the
ational Danish Civil Registration System to reflect the
dult Danish population ages 20 to 80 years. Baseline was
he first examination the individuals participated in. Blood
amples for deoxyribonucleic acid extraction were available
n 10,032 of the 10,135 participants (99%) attending the
991 to 1994 and/or 2001 to 2003 examinations.
Information on diagnosis of IHD (World Health Organi-
ation International Classification of Diseases-8th edition:
odes 410 to 414; 10th edition: I20 to I25) was collected and
erified from 1976 until July 2007 by reviewing all hospital
dmissions and diagnoses entered in the national Danish
Abbreviations
and Acronyms
CI  confidence interval
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
IHD  ischemic heart
disease
LDL-C  low-density
lipoprotein cholesterol
LDLR  low-density
lipoprotein receptor
MI  myocardial infarction
OR  odds ratio
PCSK9  proprotein
convertase subtilisin/
kexin type 9atient Registry and all causes of death entered in the national danish Causes of Death Registry. A diagnosis of MI required
he presence of at least 2 of the following criteria: characteristic
hest pain, elevated cardiac enzymes, and electrocardiographic
hanges indicative of MI (15). Follow-up was 100% complete
or both morbidity (IHD, MI) and mortality (i.e., no individ-
al was lost to follow-up). Median follow-up time was 28.7
ears (range 0 to 31.4 years). Individuals diagnosed with an end
oint before entry were excluded from Cox regression analyses,
nd those dying during follow-up were censored at their death
ate.
he CGPS study. CGPS is a cross-sectional study initi-
ted in 2003 with ongoing enrollment. Participants were
scertained from the general population exactly as at enroll-
ent in the CCHS study: data were obtained from a
uestionnaire, physical examination, and blood samples. At
he time of genotyping 31,013 had been included; of these,
,000 were used as control subjects in the CIHDS study (see
he following section), leaving 26,013 for analyses in the
GPS study. Diagnoses of IHD and MI were established
xactly as in the CCHS study, collected from registers, and
erified from 1976 until July 2007.
he CIHDS trial. CIHDS comprised 4,654 patients from
he greater Copenhagen area referred for coronary angiog-
aphy to Copenhagen University Hospital during the period
991 to 2007 and 5,000 unmatched control subjects ran-
omly selected from individuals without IHD in the CGPS
tudy. The unmatched design was selected to avoid intro-
uction of a selection bias among the remaining participants
n the CGPS study. Control subjects were excluded from
ata analysis in the CGPS study. Cases had documented
HD on the basis of characteristic symptoms of angina
ectoris (15) plus at least 1 of the following: stenosis or
therosclerosis on coronary angiography, a previous MI, or
positive exercise electrocardiography test. The diagnosis of
I was established with the same criteria as in the CCHS
nd CGPS studies. Data were available from enrollment
nd from registers from 1976 until July 2007.
aboratory analyses. Genotyping of R46L (rs11591147)
nd 3 additional nonsynonymous single-nucleotide polymor-
hisms in PCSK9 (A53V, rs11583680; I474V, rs562556; and
670G, rs505151) (16) was by TaqMan, ABI Prism
900HT (Applied Biosystems, Foster City, California).
ach run included a positive control verified by sequenc-
ng. Genotypes were verified by sequencing of all R46L
omozygotes, 20 randomly selected R46L heterozygotes,
nd 20 noncarriers.
Colorimetric and turbidimetric assays were used to mea-
ure nonfasting plasma levels of total cholesterol, high-
ensity lipoprotein cholesterol (HDL-C), and triglycerides.
he LDL-C was calculated with the Friedewald equation
hen plasma triglycerides were 4.0 mmol/l and otherwise
easured directly by a colorimetric assay (14). Non–
DL-C was total cholesterol minus HDL-C.
ther covariates. Information on diabetes mellitus, smok-
ng, and hypertension were dichotomized and defined as
iabetes (self-reported disease, use of antidiabetic medica-
t
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June 22, 2010:2833–42 PCSK9 and Ischemic Heart Diseaseion, and/or a nonfasting plasma glucose 11.0 mmol/l),
moking (current smokers), and hypertension (systolic blood
ressure 140 mm Hg, diastolic blood pressure 90 mm
g, and/or use of antihypertensive medication prescribed
pecifically for hypertension). Body mass index was weight
kg) divided by height squared (m2).
tatistical analysis. Data were analyzed with Stata/S.E.
ersion 10.1 (StataCorp, College Station, Texas). Two-
ided probability values 0.05 were considered significant.
xact uncorrected p values are given in the tables, whereas
alues corrected for multiple comparisons with the Bonfer-
oni method (significance level  0.05/number of compar-
sons) are given with symbols. Student t test and Pearson’s
hi-square test were used in 2-group comparisons.
In the prospective CCHS study, with the use of left
runcation and delayed entry, Cox proportional hazards
egression models with age as time scale were used to
stimate risk of IHD and MI. Multivariate models were
djusted for age, sex, body mass index, smoking, hyperten-
ion, diabetes mellitus, and PCSK9 A53V, I474V, and
670G genotypes. Because data were available from both
he 1991 to 1993 and 2001 to 2003 examinations of the
CHS study, we were able to take changes in risk factors
ver time into account with time-dependent covariates in
nalyses; however, results were similar when using baseline
ata only (fixed model). In the cross-sectional CGPS study
nd in the case-control CIHDS study, in which cases and
ontrol subjects were unmatched, unconditional logistic
egression analysis was used to estimate odds ratios (ORs).
ultivariate models were adjusted for age, sex, body mass
ndex, smoking, hypertension, and diabetes mellitus.
The decrease in hazard ratio (HR) for IHD for a
-mmol/l decrease in LDL-C level observed in the CCHS
tudy was used to predict theoretical HRs for IHD and
ortality (only in the CCHS study) associated with the
ecreases in LDL-C levels caused by the 46L allele in the 3
tudies, in the studies combined, and in meta-analyses. The
ecrease in HR was estimated with Cox regression analysis
ith LDL-C as a continuous variable. The observed mean
ifference in LDL-C for 46L allele carriers versus noncar-
iers in the studies was multiplied by the beta-coefficient for
he HR for IHD or mortality (only in the CCHS study)
bserved for a 1-mmol/l decrease in LDL-C and subse-
uently transformed into a theoretically predicted HR,
ssuming that the change in risk is due to the change in
DL-C alone. Observed and theoretically predicted HRs as
function of plasma LDL-C levels were corrected for
egression dilution bias with a nonparametric method (17).
isk estimates were compared with Altman’s method for
stimating differences in effect sizes (18). The HR/OR for
HD, which could be detected with 80% power and p 
.05, was 0.73 or lower in the CCHS study, 0.74 in the
IHDS study, and 0.80 in the CGPS study.
eta-analyses. To summarize results from previous stud-
es on PCSK9 R46L genotype, LDL-C levels, and risk of
HD, 2 separate meta-analyses were performed: 1 summa- iizing association between R46L genotype and LDL-C
evels in studies of general populations only, and 1 summa-
izing association between R46L genotype and risk of IHD.
elevant peer-reviewed articles were identified by searching
he PubMed EMBASE and the Genetic Association Da-
abase, limiting the search to the period January 2000
PCSK9 was first described in 2003) until June 31, 2009.
eywords used were “PCSK9 OR R46L OR pro-protein
onvertase subtilisin kexin 9 OR NARC-1” in combination
ith words related to LDL-C levels (“cholesterol,” “low-
ensity lipoprotein,” and “LDL”) and the end point (“isch-
mic heart disease,” “myocardial infarction,” “death,” “mor-
idity,” and “mortality”). All reported cases were included in
ubgroups by ethnicity, if relevant information was available.
he studies included in the 2 meta-analyses differ some-
hat, because not all studies reported both lipid levels and
isk of IHD. Funnel plots were both visually inspected and
tatistically tested for signs of publication bias with adjusted
ank correlation analysis (19) and by linear regression
nalysis (20). I2-statistics evaluated study heterogeneity.
ixed effects as well as random effects of standardized mean
ifference and OR were estimated.
The power to detect an OR of 0.5 or less at p  0.05,
orresponding to the OR initially observed for 46L allele
arriers versus noncarriers in the ARIC (Atherosclerosis
isk in Communities) study (6), ranged from 19% in the
orthwick Park Heart Study II study to 98% to 99% in the
CHS, CGPS, and CIHDS studies.
esults
e identified 241, 727, and 230 heterozygote 46L allele
arriers and 2, 3, and 1 homozygotes in the CCHS, CGPS,
nd CIHDS studies, respectively (Table 1). The frequency
f the 46L allele was 1.3% in the 45,699 individuals
xamined. Genotype distributions were in Hardy-Weinberg
quilibrium (p  0.74) (Table 1). The RL heterozygotes
nd LL homozygotes were pooled in subsequent analyses,
ow called 46L allele carriers, due to the low number of LL
omozygotes. In the CCHS study the following risk factors
or IHD were increased compared with the CGPS study
Table 1): LDL-C (difference 0.4 mmol/l), total cholesterol
0.3 mmol/l), non–HDL-C (0.4 mmol/l), and HDL-C
nversely (0.1 mmol/l), whereas the following risk factors
ere decreased: male sex (4%), age (1.8 years), body
ass index (0.9 kg/m2), smoking (7%), and hyperten-
ion (16%). Furthermore, statin use was very low in the
CHS study (3.9% vs. 9.6%), whereas the prevalence of
HD and MI was 2-fold in the CGPS study (18% vs. 9% for
HD, and 9% vs. 4% for MI). In the CIHDS study, the
ollowing risk factors were increased in cases versus ran-
omly selected control subjects from the CGPS study
Online Table 2): male sex (27%), age (1.6 years), LDL-C
0.3 mmol/l), total cholesterol (0.2 mmol/l), non–HDL-C
0.3 mmol/l), remnant cholesterol (0.1 mmol/l), HDL-C
nversely (0.4 mmol/l), triglycerides (0.2 mmol/l), body
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PCSK9 and Ischemic Heart Disease June 22, 2010:2833–42ass index (0.7 kg/m2), and diabetes mellitus (10.8%),
hereas the frequency of hypertension was decreased
22%). Statin use was almost 10-fold increased in cases
ersus control subjects (39.2% vs. 4%) (Online Table 2).
DL-C. In 46L allele carriers versus noncarriers, the 46L
llele was associated with 0.55 mmol/l (15%) lower LDL-C
evels in the CCHS study, 0.35 mmol/l (11%) in the CGPS
tudy, 0.50 mmol/l (16%) in the CIHDS study, and 0.43
mol/l (13%) in the 3 studies combined (all p  0.0001)
Table 2). Carriers of the 46L allele also had lower levels of
Characteristics of Participants in the 3 IndepenTable 1 Characteristics of Participants in th
(n 
Enrollment 1991–1994
Sex, women (%)
Age (yrs) 58.0 (
LDL-C (mmol/l) 3.6 (
Total cholesterol (mmol/l) 6.0 (
Non–HDL-C (mmol/l) 4.4 (
Remnant cholesterol (mmol/l) 0.7 (
HDL-C (mmol/l) 1.5 (
Triglycerides (mmol/l) 1.5 (
Body mass index (kg/m2) 24.9 (
Smoking
Hypertension
Diabetes mellitus
Statin use
IHD
MI
PCSK9 R46L genotype (no. of individuals)
RR 9,
RL
LL
Data are from the 1991 to 1994 or 2001 to 2003 examinations of the
collected, from study enrollment 2003 to 2007 for the CGPS study (C
2007 in the CIHDS study (Copenhagen Ischemic Heart Disease Study)
indicated. In the CCHS study (1991 to 1994 examination), low-den
lipoprotein cholesterol (HDL-C) and the relative frequencies of women,
in the CGPS study (2003–ongoing); whereas age; HDL-C; body mass
individuals treated with statin were lower. In the CIHDS study (1991–o
and hypertension were lower than in the CGPS study, whereas the r
*p  0.001, comparing the 2 general population studies, the CCHS v
DL-C as a Function of PCSK9 R46L GenotypeTable 2 LDL-C as a Function of PCSK9 R46L Genotype
Number of Individuals
(46L Allele Carriers)
LDL-C (m
Noncarriers 4
All
CCHS 10,032 (243) 3.7 (0.01)
CGPS 26,013 (730) 3.3 (0.006)
CIHDS 9,654 (231) 3.2 (0.01)
All 45,699 (1,204) 3.4 (0.005)
Statin users excluded
CCHS 9,634 (238) 3.7 (0.01)
CGPS 23,521 (695) 3.4 (0.006)
CIHDS 7,431 (222) 3.4 (0.01)
All 40,586 (1,155) 3.4 (0.005)alues are mean and SEM or percentages. Noncarriers  RR homozygotes; 46L allele carriers  RL hete
Abbreviations as in Table 1.otal cholesterol (6% to 9%), non–HDL-C (9% to 13%),
nd apolipoprotein B (8% to 13%) than noncarriers (p 
.001). The LDL-C levels in 46L allele carriers were consis-
ently lower than in noncarriers from 20 to 80 years of age in
oth studies of general populations (Fig. 1).
HD, MI, and mortality. In the prospective CCHS study,
omprising 10,032 individuals, PCSK9 R46L genotype did
ot predict risk of IHD (multifactorially adjusted HR: 0.94;
5% confidence interval [CI]: 0.68 to 1.31; p 0.73) or MI
HR: 1.13; 95% CI: 0.73 to 1.75; p  0.57) (Table 3). In
Studiesndependent Studies
32)
CGPS
(n  26,013)
CIHDS
(n  9,654)
001–2003 2003–ongoing 1991–ongoing
51% 42%†
)* 59.8 (51–69) 60.0 (51–69)
4)* 3.2 (2.6–3.9) 3.1 (2.5–3.9)
9)* 5.7 (5.0–6.4) 5.4 (4.6–6.2)†
3)* 4.0 (3.2–4.8) 4.0 (3.3–4.8)
0) 0.7 (0.5–1.0) 0.7 (0.5–1.0)
8)* 1.6 (1.3–2.0) 1.4 (1.1–1.8)†
2) 1.5 (1.0–2.2) 1.5 (1.0–2.4)
7.9)* 25.8 (23.4–28.6) 26.0 (23.6–28.8)
55% 52%†
68% 48%†
4.5% 6.5%†
* 9.6% 24.2%†
9% 48.2%†
4% 23.1%†
25,283 9,581
727 230
3 1
study (Copenhagen City Heart Study) when deoxyribonucleic acid was
gen General Population Study), and from study enrollment 1991 to
are median and interquartile range or percentages unless otherwise
protein cholesterol (LDL-C), total cholesterol, and non–high-density
ic heart disease (IHD), and myocardial infarction (MI) were higher than
and the relative frequencies of current smoking, hypertension, and
, total cholesterol and HDL-C and the relative frequencies of smokers
frequencies of diabetes mellitus, statin use, IHD, and MI were higher.
e CGPS. †p  0.001, comparing the CIHDS versus the CGPS.
LDL-C Difference
(mmol/l)
LDL-C Difference
(%) *p Valueele Carriers
(0.07) 0.55 (0.08) 15% 0.0001
(0.03) 0.35 (0.04) 11% 0.0001
(0.07) 0.50 (0.08) 16% 0.0001
(0.03) 0.43 (0.03) 13% 0.0001
(0.07) 0.50 (0.08) 14% 0.0001
(0.04) 0.40 (0.006) 12% 0.0001
(0.08) 0.58 (0.09) 17% 0.0001
(0.03) 0.46 (0.03) 14% 0.0001dente 3 I
CCHS
10,0
and 2
55%*
44–69
2.9–4.
5.1–6.
3.5–5.
0.5–1.
1.2–1.
1.0–2.
22.5–2
48%*
52%*
4.1%
3.9%
18%*
9%*
789
241
2
CCHS
openha
. Values
sity lipo
ischem
index;
ngoing)mol/l)
6L All
3.1
2.9
2.7
2.9
3.2
3.0
2.8
3.0rozygotes and LL homozygotes. *46L allele carriers versus noncarriers.
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June 22, 2010:2833–42 PCSK9 and Ischemic Heart Diseasehe cross-sectional CGPS study, comprising 26,032 indi-
iduals, PCSK9 46L allele carriers had a 46% reduction in
isk of IHD (OR: 0.54; 95% CI: 0.39 to 0.77; p  0.001)
nd a 58% reduction in risk of MI (OR: 0.42; 95% CI: 0.23
o 0.76; p 0.004) compared with noncarriers (Table 3). In
he case-control CIHDS study, comprising 4,654 cases
ersus 5,000 unmatched control subjects, R46L genotype
as not associated with risk of IHD (OR: 0.82; 95% CI:
.55 to 1.21; p  0.32) or MI (OR: 1.11; 95% CI: 0.72 to
.73; p  0.63) (Table 3). Risk of IHD for 46L allele
arriers was lower in the CGPS than in the CCHS study
p  0.05), and risk of MI in the CGPS study was lower
han in both the CCHS study (p  0.004) and the
IHDS study (p  0.005) (Table 3). After exclusion of
tatin users or after adjustment for PCSK9 A53V, I474V,
Figure 1 LDL Cholesterol Levels by
Age and PCSK9 R46L Genotype
Low-density lipoprotein (LDL) cholesterol levels as a function of age by PCSK9
R46L carrier status in 2 general population samples, The Copenhagen City Heart
Study, n  10,032 (top), and the Copenhagen General Population Study, n 
26,013 (bottom). Noncarriers  RR homozygotes; 46L carriers  RL heterozy-
gotes and LL homozygotes. Number of noncarriers (open diamonds) and 46L
allele carriers (closed diamonds) are given below the x-axis of each study.nd E670G (16), results were similar. CCombining the 3 studies into 1 large study comprising
,830 cases and 36,869 control subjects, 46L allele carriers
ad a 30% reduction in risk of IHD compared with
oncarriers (OR: 0.70; 95% CI: 0.58 to 0.86; p  0.001)
Table 3). In a post-hoc subgroup analysis, the cardiopro-
ective effect of the 46L allele was similar in individuals at or
elow the median age of 60 years (OR: 0.70; 95% CI: 0.50
o 0.95), and in individuals above the median age of 60 years
OR: 0.71; 95% CI: 0.56 to 0.91; p value for interaction
etween age and genotype on risk of IHD  0.49).
In the prospective CCHS study, carrying the 46L allele
as not associated with a reduction in all-cause mortality
OR: 1.18; 95% CI: 0.93 to 1.50; p  0.17) or with
ortality due to IHD (OR: 1.35; 95% CI: 0.72 to 2.54; p
.34) (Table 3).
eta-analyses. In a meta-analysis including 7 general pop-
lation studies with a total of 1,639 46L allele carriers and
9,198 noncarriers, standardized mean differences in LDL-C
evels between 46L allele carriers and noncarriers were 0.43
mol/l (95% CI:0.48 to0.38 mmol/l) and0.44 mmol/l
95% CI: 0.51 to 0.37 mmol/l) in fixed and random effect
odels, respectively (Fig. 2), corresponding to a 12% lower
DL-C level in 46L allele carriers. I2, a measure of heteroge-
eity between studies, was 38% (p  0.14).
In a meta-analysis combining studies on risk of IHD
11,339 cases and 55,359 control subjects), 46L allele
arriers versus noncarriers had a reduction in risk of IHD of
8% with a fixed effect OR of 0.72 (95% CI: 0.62 to 0.84)
nd random effect of 0.72 (95% CI: 0.57 to 0.93) and an I2
f 40% (p  0.06) (Fig. 3). In a meta-analysis including the
studies from Copenhagen, 46L allele carriers versus
oncarriers had a reduction in risk of IHD of 23% with a
xed effect OR of 0.77 (95% CI: 0.65 to 0.92) and random
ffect of 0.77 (95% CI: 0.55 to 1.07). However, I2 was 72%
p  0.03), suggesting variability between studies (Fig. 3).
In both meta-analyses (Figs. 2 and 3), Begg’s test
emonstrated an equal distribution of studies above and
elow the log OR line (p 0.88 and p 0.65, respectively),
nd there was also no indication of asymmetry of studies
istributed at higher variances (p  0.86 and p  0.30,
espectively, by Egger’s test), suggesting absence of publi-
ation bias in meta-analyses.
heoretically predicted versus observed risk of IHD and
ortality. The observed mean reductions in plasma
DL-C of 15% (0.55 mmol/l) in the CCHS study, 11%
0.35 mmol/l) in the CGPS study, and 16% (0.53 mmol/l)
n the CIHDS study theoretically predicted risk reductions
or IHD of 5% (OR: 0.95; 95% CI: 0.92 to 0.98), 4% (OR:
.96; 95% CI: 0.94 to 0.98), and 6% (OR: 0.94; 95% CI:
.91 to 0.97), respectively (Fig. 4, left and middle panels),
nd a nonsignificant reduction of 4% (OR: 0.96; 95% CI:
.93 to 1.01) in all-cause mortality, assuming that the
eduction in risk was due to a long-lasting lower LDL-C
evel alone. The corresponding observed risk reductions for
HD were 6% (OR: 0.94; 95% CI: 0.68 to 1.31) in the
CHS study, 46% (OR: 0.54; 95% CI: 0.39 to 0.77) in the
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PCSK9 and Ischemic Heart Disease June 22, 2010:2833–42GPS study, and 18% (OR: 0.82; 95% CI: 0.55 to 1.21) in
he CIHDS study (Fig. 4, right panel). The p values for
ifferences between predicted and observed risks were 0.48
or the CCHS study,0.001 for the CGPS study, and 0.25
or the CIHDS study. The observed risk for all-cause
ortality was 1.18 (95% CI: 0.93 to 1.50; p  0.06 for
redicted vs. observed risk).
For all 3 studies combined, the corresponding predicted
nd observed risk reductions for IHD were 5% (OR: 0.95,
5% CI: 0.93 to 0.98) and 30% (OR: 0.70; 95% CI: 0.58 to
.86) (p value for difference  0.004). For studies included
n the meta-analysis on risk of IHD, predicted and observed
isk reductions were 5% (OR: 0.95; 95% CI: 0.93 to 0.98)
nd 28% (OR: 0.72; 95% CI: 0.62 to 0.84) (p value for
ifference 0.001) (Fig. 4).
iscussion
he main findings of the present studies were: 1) the
CSK9 46L allele was consistently associated with a 0.35-
isk of IHD, MI, and Mortality in PCSK9 46L Allele Carriers VersusTable 3 Risk of IHD, MI, and Mortality in PCSK9 46L Allele Ca
46L Allele Carriers
Control Subjects Events/Cases
IHD
All
CCHS 8,269 (204) 1,763 (39)
CGPS 23,600 (690) 2,413 (40)
CIHDS 5,000 (118) 4,654 (113)
All 36,869 (1,012) 8,830 (192)
Statin users excluded
CCHS 8,081 (202) 1,553 (36)
CGPS 22,133 (673) 1,388 (22)
CIHDS 4,801 (116) 2,630 (106)
All 35,015 (991) 5,571 (164)
MI
All
CCHS 8,269 (204) 858 (24)
CGPS 23,600 (690) 1,011 (12)
CIHDS 5,000 (118) 1,764 (42)
All 36,869 (1,012) 3,633 (78)
Statin users excluded
CCHS 8,081 (202) 730 (23)
CGPS 22,133 (673) 452 (4)
CIHDS 4,801 (116) 613 (13)
All 35,015 (991) 1,795 (40)
All-cause mortality
All
CCHS 7,087 (169) 3,031 (74)
Statin users excluded
CCHS 6,775 (166) 2,945 (72)
IHD mortality
CCHS 9,550 (224) 368 (19)
he p values are not corrected for multiple comparisons. Multifactorial adjustment was for sex
p  0.008 corrected for multiple comparisons with the Bonferroni method (required significance
IHDS, p  0.005.
CI  confidence interval; HR  hazard ratio; OR  odds ratio; other abbreviations as in Table 1o 0.55-mmol/l lower LDL-C from 20 to 80 years; 2) the s6L allele was associated with reduced risk of IHD in the
argest study only, the CGPS study, and in the studies
ombined; 3) the 46L allele did not predict mortality; and
) in the CGPS study and in the combined analyses, the
ssociation of the 46L allele with IHD risk seemed dispro-
ortionately greater than expected from the effect of the
olymorphism on LDL-C alone.
In the 2 studies of the general population, the CCHS and
he CGPS studies, we show that the 11% to 15% reduction
n LDL-C levels in 46L allele carriers versus noncarriers is
resent from the age of 20 years and persists throughout life.
hese results are in accordance with the 9% to 15%
eduction found in previous studies of adult populations
6,7,10,21,22). The Bogalusa Heart Study, comprising
,564 school children (mean age 9.4 years) reported similar
2% lower LDL-C levels, suggesting that the reduction in
DL-C might be lifelong (8).
Despite a consistent reduction in LDL-C levels in 46L
llele carriers versus noncarriers, risk estimates for IHD
carriers in the CCHS, CGPS, and CIHDSVersus Noncarriers in the CCHS, CGPS, and CIHDS
Age- and Sex-Adjusted Multifactorially Adjusted
R/OR (95% CI) p Value HR/OR (95% CI) p Value
.94 (0.69–1.30) 0.71 0.94 (0.68–1.31)* 0.73
.56 (0.40–0.78) 0.001† 0.54 (0.39–0.77) 0.001†
.85 (0.65–1.12) 0.62 0.82 (0.55–1.21) 0.32
.74 (0.61–0.89) 0.001† 0.70 (0.58–0.86) 0.001
.98 (0.71–1.36) 0.93 0.97 (0.69–1.37) 0.88
.51 (0.33–0.78) 0.002† 0.47 (0.29–0.74) 0.001†
.88 (0.64–1.21) 0.44 0.79 (0.48–1.30) 0.35
.75 (0.61–0.91) 0.002† 0.66 (0.52–0.84) 0.001†
.22 (0.81–1.83) 0.34 1.13 (0.73–1.75)‡ 0.57
.41 (0.23–0.74) 0.003† 0.42 (0.23–0.76) 0.004†
.02 (0.71–1.46) 0.93 1.11 (0.72–1.73)§ 0.63
.79 (0.63–1.00) 0.05 0.82 (0.63–1.06) 0.12
.35 (0.89–2.04) 0.16 1.23 (0.79–1.92) 0.36
.29 (0.11–0.77) 0.01 0.30 (0.11–0.82) 0.02
.87 (0.49–1.53) 0.62 0.94 (0.51–1.73) 0.84
.79 (0.57–1.09) 0.16 0.80 (0.58–1.11) 0.19
.11 (0.88–1.40) 0.38 1.18 (0.93–1.50) 0.17
.08 (0.85–1.37) 0.53 1.14 (0.90–1.45) 0.27
.24 (0.67–2.34) 0.49 1.35 (0.72–2.54) 0.34
ody mass index, smoking, hypertension, and diabetes mellitus. *CCHS versus CGPS, p  0.05.
0.05/number of comparisons/end point [ 6]). ‡CCHS versus CGPS, p  0.004. §CGPS versusNonrriers
H
0
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0
0
0
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, age, b
level eem to vary somewhat (6,7,21). In the 3 present studies,
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June 22, 2010:2833–42 PCSK9 and Ischemic Heart Diseaselthough the reduction in LDL-C in 46L allele carriers
ersus noncarriers is consistent between studies, risk esti-
ates for IHD cover a spectrum from nonsignificant
eductions of 6% and 18% in the CCHS and CIHDS
tudies, respectively, to a significant 46% reduction in risk in
he CGPS study. Part of this variability could be due to
ifferences in study designs and thus in ascertainment of
ndividuals for studies (CCHS, prospective; CGPS, cross-
ectional; CIHDS, case-control). Other factors that could
nfluence risk associated with the 46L allele are changes in
isk factors for IHD and changes in treatment and in risk of
HD in the population over time, from the start of enroll-
ent in the CCHS study and the CIHDS study in 1991 to
nrollment in the CGPS study in 2003 and onwards.
uring the study period there has been a reduction in
ietary fat intake in the Danish general population (44
nergy% in 1985 vs. 34 energy% in 2002), an increase in
tatin treatment, and a reduction in risk of IHD from
26/100,000 in 1985, to 173/100,000 in 2002 (Danish
ational Board of Health). These trends are also reflected
n a general reduction in lipid risk factors for IHD in the
GPS study versus the CCHS study, an almost 150%
ncrease in statin treatment, and a 50% reduction in risk of
Figure 2 Meta-Analysis of PSCK9 R46L Genotype and LDL Cho
Meta-analysis of general population studies of whites of PSCK9 R46L genotype an
proportional to the weight ( 1/[standard error of effect size]2) of each study, and
and dashed vertical line represent the summary estimate of standardized mean d
mond. The solid vertical line corresponds to difference in LDL cholesterol  0 bet
riers  RR homozygotes; 46L allele carriers  RL heterozygotes and LL homozygotes
were not reported for blacks in this study); BHS  Bogalusa Heart Study; CCH
MDCS  Malmö Diet and Cancer Study; NPHSII  Northwick Park Heart Studyoth IHD and MI, although other risk factors increased tbody mass index, current smokers, and hypertension). This
eneral reduction in lipid risk factors, especially LDL-C,
nd in risk of IHD in the general population over time
hanges the context in which the PCSK9 46L allele might
xert its effect on risk, from the start of enrollment of the
CHS participants and the CIHDS cases (1991) to the
tart of enrollment of CGPS participants (2003) or perhaps
ore generally from high-risk to lower-risk populations,
espite a consistent effect of the 46L allele on plasma levels
f LDL-C.
The 5% theoretically predicted risk reduction for IHD in
6L allele carriers versus noncarriers, estimated from the
isk reduction associated with a 1-mmol/l reduction in
DL-C, was less than the 30% reduction observed in our 3
tudies combined and less than the 28% risk reduction
bserved in meta-analysis, suggesting either that: 1) the
CSK9 46L allele might reduce risk by an additional
echanism unrelated to the LDL-C lowering effect (3),
lthough no lipid independent effects of PCSK9 have so far
een demonstrated in functional studies in vitro or in vivo;
r 2) PCSK9 genotype is a better predictor of the effect on
isk of IHD of lifelong exposure to LDL-C than LDL-C
easured in adult life. Genotypes are present from concep-
rol Levels
density lipoprotein (LDL) cholesterol levels. On the forest plot, the box area is
orizontal lines correspond to the 95% confidence intervals (CIs). The diamonds
ces, and the CI for the summary estimate corresponds to the width of the dia-
46L carriers and noncarriers. Test for heterogeneity: all studies, I2  38%. Noncar-
 Atherosclerosis Risk in Communities Study (lipid levels by R46L genotype
openhagen City Heart Study; CGPS  Copenhagen General Population Study;
BASZ  National Health Survey in Poland.leste
d low-
the h
ifferen
ween
. ARIC
S  C
II; WOion, and as Cohen et al. (6) and Brown and Goldstein (13)
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PCSK9 and Ischemic Heart Disease June 22, 2010:2833–42ave pointed out, genotypes associated with LDL-C might
herefore most accurately reflect lifelong exposure to
DL-C. If the lower risk seen in R46L carriers is due to the
ifelong reduction in LDL-C, early long-term lipid-
owering therapy might be more beneficial than therapy
nstituted later in life (13).
In the prospective CCHS study, neither the HRs for
HD or MI nor the HRs for mortality predicted by the 46L
llele were different from those of noncarriers (HRs over-
apped 1.00). In this study, a 1-mmol/l decrease in LDL-C
redicted a 6% decrease in all-cause mortality (OR: 0.94;
5% CI: 0.90 to 0.98), and the 0.55-mmol/l decrease in
DL-C observed in the CCHS study predicted a nonsig-
ificant 4% decrease (96%) (OR: 0.96; 95% CI: 0.93 to
.01) in total mortality, which was not different from what
e observed. However, if we believe the HR for IHD from
he meta-analysis of our 3 studies and from most of the
revious studies on IHD risk, mortality—like risk of
HD—is also likely to be reduced more than predicted by
he effect on LDL-C, especially in populations at lower risk,
uch as the CGPS study.
tudy limitations. The present studies have limitations
Figure 3 Meta-Analysis of PSCK9 R46L Genotype and Risk of I
Meta-analysis of studies of the association between PSCK9 R46L genotype and ri
weight ( /[standard error of effect size]2) of each study, and the horizontal lines
summary estimate, and the CI for the summary estimate corresponds to the width
equivalent to no effect of genotype. Test for heterogeneity: all studies, I2  40%;
lower for the individual study (p  0.05); an OR of 0.5 corresponds to the OR obs
of a false negative result for a given study is 100%-power. †A p value 0.05 indic
CIHDS  Copenhagen Ischemic Heart Disease Study; CO  case-only; GP  gene
other abbreviations as in Figure 2.i.e., selection bias and misclassification of the diagnosis sf IHD). However, the general populations used were
elected with the Danish Central Person Registry, draw-
ng 2 random samples from the Danish adult general
opulation without knowledge of genotypes, plasma
DL-C levels, or IHD status. Response rates in the
CHS study were comparable to those of other large
pidemiologic studies (23,24). In the CCHS study, blood
amples for deoxyribonucleic acid analysis were not col-
ected until the 1991 to 1994 examination and the
ubsequent 2001 to 2003 examination. Thus, the present
tudy is based on participants who survived until the 1991
o 1994 examination (or who were invited for the first
ime at the time of this examination or for the 2001 to
003 examinations). Survivor bias might potentially limit
he generalizability of the results but not the internal
alidity. A number of observations argue against survivor
ias: 1) the original cohort was supplemented with
ounger individuals at all 3 follow-up examinations; 2)
he genotype distribution for PCSK9 R46L did not differ
rom that predicted by the Hardy-Weinberg equilibrium;
) HR for all-cause mortality in 46L-allele carriers was
imilar to noncarriers; and 4) the 46L allele frequency was
mic Heart Disease
schemic heart disease. On the forest plot, the box area is proportional to the
pond to the 95% CIs. The diamonds and dashed vertical line represent the
diamond. The solid vertical line corresponds to an odds ratio (OR)  1 and is
CGPS, and CGPS studies, I2  72%. *The power to detect an OR of 0.5 or
in the first study on the PCSK9 R46L genotype (6); it follows that the probability
hat the genotype is not in Hardy-Weinberg (H-W) equilibrium. CC  case-control,
ulation; PROSPER  Prospective Study of Pravastatin in the Elderly at Risk;sche
sk of i
corres
of the
CCHS,
erved
ates t
ral popimilar to that found in other studies of Caucasians. We
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June 22, 2010:2833–42 PCSK9 and Ischemic Heart Diseaseave complete follow-up on morbidity and mortality for
ll participants; however, the definition of IHD and
ackground therapy might have varied over time or might
ave been incorrectly coded in the Danish National
atient Registry or some individuals might not have had
HD yet. Such potential limitations can be assumed to be
venly distributed between carriers and noncarriers and
herefore would result in more conservative risk estimates
or the association of genotype with risk of IHD. Finally,
ur 3 studies differ in number of participants, and
herefore all estimates from the combined studies or from
eta-analyses are mainly driven by the comparatively
arge CGPS study.
onclusions
he PCSK9 46L allele was associated with reductions in
DL-C of 11% to 16% in all age groups from 20 to 80
ears in the general population. The 30% reduction in risk
f IHD observed in our 3 studies combined was larger than
redicted by the reduction in LDL-C alone. This could be
ecause genotype is a better predictor of lifelong exposure to
DL-C than LDL-C measured in adult life.
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